聚乙二醇干扰素α-2α治疗HCV/HIV共感染临床疗效  

Anti-Viral Therapy with Pegylated Interferon Alpha-2α Plus Ribavirin in Patients with Co-Infected of HBV and HCV

作　　者：宋晓丹[1] 马玉梅[1] 李永红[1] 

机构地区：[1]沈阳市第六人民医院,辽宁沈阳110006

出　　处：《肿瘤学杂志》2017年第11期1016-1018,共3页Journal of Chinese Oncology

基　　金：辽宁省建平县肝脏疾病高发综合防治科技惠民示范工程(2013GS210102);国家自然科学基金项目(81403271)

摘　　要：[目的]研究慢性丙型肝炎(CHC)与丙型肝炎病毒/人类免疫缺陷病毒(HCV/HIV)共感染者用聚乙二醇干扰素α-2a(PEG-IFNα-2a)抗病毒治疗疗效的观察。[方法]治疗前后定期采集30例CHC(HCV组)、30例HCV/HBV共感染者的外周血,检测HCV RNA、血常规和肝功酶谱指标。[结果]治疗后HCV组的HCV-RNA阴转率(73.33%)和PLT(227.13±79.34)均高于共感染组(20%、177.73±66.05),ALT、AST及APRI评分分别为(57.90±24.67、61.60±25.27、0.80±0.54)均低于共感染组(77.90±30.20、76.33±28.60、1.20±0.58)。[结论 ]PEG-IFNα-2a抗病毒治疗HCV/HIV共感染者疗效较单纯丙型肝炎患者差,并且对造血系统的影响较大,建议有条件的患者应用直接抗病毒药物。[Objective] To evaluate the anti-viral therapy with PEGylated interferon alpha-2α plus ribavirin in patients with co-infection of HCV and HIV. [Methods] Thirty patients infected with HCV （HCV group） and 30 patients co-infected with HCV and HIV （HCV/HIV group） undergoing anti-viral therapy were enrolled in the study. HCV RNA,blood and liver enzymes were examined. [Results] After treatment,the HCV-RNA negative conversion rate（73.33%）and PLT（227.13±79.34）of HCV group were higher than those of HCV/HIV group（20%,177.73±66.05）; and the ALT,AST and APRI scores（57.90±24.67,61.60±25.27 and 0.80±0.54） were lower than those of HCV/HIV group（77.90±30.20,76.33±28.60 and 1.20±0.58）. [Conclusion] The efficacy of PEG-IFN-α plus ribavirin therapy is less effective and the adverse effect for hematopoietic system is more severe in HCV/HIV co-infected patients than that in HCV patients,therefore direct-acting antiviral agents are recommended for those patients.

关 键 词：人类免疫缺陷病毒 丙型肝炎病毒 共感染 

分 类 号：R735.7[医药卫生—肿瘤]